Sign In
Buy DVA
$195.03
+7.14 (+3.80%)
At Close: Jun 03, 2026
DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
01:57pm, Monday, 17'th Nov 2025
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe
DaVita Inc. to Participate in Fireside Chat with Wolfe Research
04:16pm, Friday, 14'th Nov 2025
DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Co
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
08:00am, Tuesday, 04'th Nov 2025
Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNews
Y Intercept Hong Kong Ltd Takes $1.24 Million Position in DaVita Inc. $DVA
04:03am, Tuesday, 04'th Nov 2025
Y Intercept Hong Kong Ltd bought a new stake in DaVita Inc. (NYSE: DVA) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 8,725 shares
Bessemer Group Inc. Sells 3,846 Shares of DaVita Inc. $DVA
03:35am, Monday, 03'rd Nov 2025
Bessemer Group Inc. cut its position in shares of DaVita Inc. (NYSE: DVA) by 54.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commis
3 Warren Buffett Stocks to Buy Hand Over Fist in November
01:07pm, Sunday, 02'nd Nov 2025
DaVita is cheap considering its long-term growth potential. Buy Kraft Heinz for its high yield, stay for the restructuring that could unlock the food company's underlying value.
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
03:01pm, Thursday, 30'th Oct 2025
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
Asset Management One Co. Ltd. Reduces Stock Position in DaVita Inc. $DVA
04:48am, Thursday, 30'th Oct 2025
Asset Management One Co. Ltd. lowered its stake in DaVita Inc. (NYSE: DVA) by 10.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. T
Sumitomo Mitsui Trust Group Inc. Grows Position in DaVita Inc. $DVA
04:06am, Thursday, 30'th Oct 2025
Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of DaVita Inc. (NYSE: DVA) by 4.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange C
DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript
07:46pm, Wednesday, 29'th Oct 2025
DaVita Inc. ( DVA ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Nic Eliason - Group Vice President of Investor Relations Javier Rodriguez - CEO & Executive Director Joel Ac
DaVita HealthCare (DVA) Q3 Earnings Lag Estimates
06:26pm, Wednesday, 29'th Oct 2025
DaVita HealthCare (DVA) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $2.59 per share a year ago.
DaVita misses quarterly profit estimates on rising costs, lower volumes
05:32pm, Wednesday, 29'th Oct 2025
DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.
DaVita Inc. 3rd Quarter 2025 Results
04:05pm, Wednesday, 29'th Oct 2025
DENVER , Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our
Ethic Inc. Grows Stock Position in DaVita Inc. $DVA
03:37am, Wednesday, 29'th Oct 2025
Ethic Inc. grew its position in DaVita Inc. (NYSE: DVA) by 36.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
12:31pm, Tuesday, 28'th Oct 2025
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
